Nuclear molecular imaging – in vivo


The nuMIx lab is specialized in preclinical nuclear imaging in vivo and ex vivo. nuMix is proposing services in in vivo preclinical nuclear imaging by PET, SPECT and CT using last generation cameras (Bioscan, USA).

Nuclear Molecular Imaging relies on the detection of γ photons emitted by radioactive labels, i.e., radiotracers. These radiotracers are selected molecules typical for specific metabolic pathways that are made visible to the detection system after labelling with some appropriate radionuclide. This imaging technique delivers images depicting the radiotracer distribution, which reflects the function or metabolic activity of organs, tissues or tumours.

Positron Emission Tomography (PET) requires short half-life radionuclides usually produced in a cyclotron ; a PET camera generates essentially 3D quantitative images with extremely high sensitivity (< pM).

Single Photon Emission Computed Tomography (SPECT) is based on radiotracers different than those used in PET, usually with a longer half-life, which allows to carry out follow-up imaging studies. Spatial resolution of these images is similar to that of PET, and is in the order of mm, however, the sensitivity of this method is noticeably lower. Nevertheless, SPECT allows imaging of different radiotracers simultaneously.

X-ray Computed Tomography (X-CT) yields structural/anatomical highresolution 3D images based on the differential attenuation of X-rays in biological tissues. This imaging modality complements the metabolic or functional images obtained with PET or SPECT.


  1. NanoPET/CT (Bioscan, USA)
  2. NanoSPECT (Bioscan, USA)


Facility manager Academic supervisor

Nuclear molecular imaging – in vivo